SMART Antiviral Prize is sponsored by BARDA DRIVe. SMART Antiviral Prize is a competition from BARDA DRIVe that funds development of novel broad-spectrum small molecule antivirals targeting the Flaviviridae and Togaviridae virus families, addressing gaps in the U.

Smart Antiviral Prize 2026 – VITAL Hub Funding Expanded! Increased prize pool and Stage 1 opportunities – creating more pathways for teams to advance.

Join an Upcoming Info Session → $100M SMART Antiviral Prize to Advance Novel Antiviral Therapies The SMART Antiviral Prize is focused on identifying safe and effective broad-spectrum small molecules that have the potential to advance into clinical trials and achieve U.S. regulatory approval.

The goal of this competition is to advance the development of novel antivirals that strengthen the therapeutic pipeline and address gaps in strategic preparedness in partnership with innovators offering creative solutions.

Desired Product Attributes Seeking Novel Therapeutic Solutions for Emerging Viral Diseases for Which No The SMART Antiviral Prize focuses on supporting the development of antivirals with broad-spectrum activity against members of the Togaviridae and/or Flaviviridae families. There are currently no FDA-approved broad-spectrum antivirals for any viruses within these families—which include dengue, Zika, West Nile, and Chikungunya.

These viruses collectively cause millions of infections each year, including increasing numbers of cases in the United States. Up to 8 prizes, $2. 5M each Up to 7 prizes, $7.

5M each Now with Increased Funding! Start here to prepare your Concept Stage submission. Review the criteria, explore requirements, and submit when ready.

Desired Product Attributes This document outlines the Desired Product Attributes that applicants may find useful when shaping antiviral concepts for submission to the SMART Antiviral Prize. Evaluation Process & Criteria The SMART Antiviral Prize uses a two-stage review process. This document outlines the Evaluation Process & Evaluation Criteria for the Concept Stage.

Review frequently asked questions, program stage overviews, and general resources for the SMART Antiviral program Concept Stage engagement and application. Apply now to submit your Concept Stage antiviral innovation tor funding and support through the SMART Antiviral Prize.

Turning Breakthrough Science Into Life-Saving Antiviral Therapies The SMART Antiviral Prize is more than a competition – it’s a call to advance bold ideas and move promising science forward. Rewarding Translational Scientific Breakthroughs Using a Tiered, Sequenced Prize Design Participation in the SMART Antiviral Prize is subject to official Terms & Conditions .

The SMART Antiviral Prize is focused on identifying safe and effective broad-spectrum small molecules that have the potential to advance into clinical trials and achieve U.S. regulatory approval. The goal of this competition is to advance the development of novel antivirals that strengthen the therapeutic pipeline and address gaps in strategic preparedness in partnership with innovators offering creative solutions.

A Multi-Stage Competition The SMART Antiviral Prize is a multi-stage competition designed to move candidates from idea to IND readiness through clear, stage-specific milestones and published evaluation criteria.

It begins with a Concept Stage that prioritizes a well-defined technical and development approach (not extensive data), with later stages requiring progressively deeper technical submissions and evidence of broad-spectrum activity and product attributes—while allowing multiple entry points as candidates advance. Participation in the SMART Antiviral Prize is subject to official Terms & Conditions .

If you or your organization would like to explore collaborations with other innovators for potential joint collaborative applications, please visit the SMART Antiviral Prize Teaming Page. Upcoming Info Sessions & Webinars Have questions about the SMART Antiviral Prize? Join one of our upcoming info sessions to learn more about the challenge, the application process, and what we’re looking for.

You’ll also have the opportunity to engage directly with the VITAL team during a live Q&A. Call for Antiviral Testing Partners Do you have capabilities in running live-virus, cell-based antiviral potency assays for Dengue and Chikungunya and are interested in serving as a reference facility for the SMART Antiviral Prize? All information provided within is preliminary and subject to change.

Specific criteria and requirements are currently being refined. In the event of any inconsistency, the official SMART Antiviral Prize Terms & Conditions supersede this information. Objectives for Each Stage of the SMART Antiviral Prize Describe development plans to discover or advance broad-spectrum small molecule antivirals for Flaviviridae and/or Togaviridae families.

Identify at least one promising chemical series with reproducible cell-based antiviral activity and an early SAR that supports rational optimization. Build an initial “go/no-go” dataset for each series—basic ADME/PK, key developability flags, and early safety/DDI triage—to justify moving into lead optimization.

Stage 2: Lead Optimization Optimize potency, selectivity, and exposure to produce a well-characterized lead and backup, with a clear plan to mitigate remaining liabilities. Demonstrate in vivo proof-of-concept efficacy in a relevant animal model and nominate an IND candidate (and backup where feasible) suitable for IND-enabling studies.

Complete the nonclinical package required for first-in-human dosing, including GLP toxicology/safety pharmacology and definitive ADME/DDI studies, plus manufacturing/CMC readiness (quality, stability, and formulation appropriate for clinical use). Conduct appropriate FDA interactions and assemble an IND-ready submission package suitable for filing to initiate clinical trials.

A Multi-Stage Model to Accelerate Antiviral Innovation The SMART Antiviral Prize offers up to $100M in awards to support innovators across four progressive stages – from early concept through IND readiness. Each stage builds upon prior success, rewarding the most promising candidates for achieving ambitious yet attainable milestones on an accelerated timeline.

Stage Launch & Declaration of Intent Open Feb 2 – May 11, 2026 Up to seven – up to $7.

5M each Stage Launch & Declaration of Intent Stage 2: Lead Optimization Stage Launch & Declaration of Intent Stage Launch & Declaration of Intent Award Allocation across Concept Stage and Stage 1: Hit-to-Lead The SMART Antiviral Prize fosters the growth of early-stage innovators by providing seed funding at the Concept Stage, and by reserving two awards in Stage 1 for Concept Stage winners.

Teams with candidates already in preclinical development can enter Stage 1 without having participated in the Concept Stage. Up to eight awards will be made after a merit-based review of all proposals. Submissions will be reviewed as a batch after the solicitation period is closed.

Applications will be accepted starting in early February 2026. Concept Stage award decisions are anticipated in Q3 2026. The evaluation process and accompanying criteria are outlined below.

Awards for Stage 1: Hit-to-Lead Up to seven awards will be made in total. Up to three (3) of the seven awards are reserved exclusively for Concept Stage winners that meet the Optimal or Essential Success Criteria within the specified submission window. * All applicants must submit a Declaration of Intent and receive approval before their submissions can be reviewed.

Rolling Review (First-to-Finish)*: Data packages may be submitted at any time during the submission window (anticipated to open in early 2027). Submissions will be reviewed in the order received, and awards will be made on a first-to-finish basis, subject to validation of the data.

Two-Success Criteria Tracks: Data packages may be submitted against one of two success criteria: Optimal Success Criteria or Essential Success Criteria, as defined in the Target Compound Profile . Optimal Track: Awards for Optimal submissions will be made on a rolling basis as soon as the data are reviewed and validated, until all available prizes for Stage 1 (that have not been reserved for Concept Stage winners) are awarded.

Essential Track: Submissions that meet only the Essential Success Criteria will be held and considered at the end of the submission period. Essential awards will be made only if funding remains after all Optimal awards have been issued. Reserved Awards for Concept Stage Winners: The three reserved awards are available only to eligible Concept Stage winners and may be earned at any time during the submission window.

These reserved awards will be issued to the first three Concept Stage winners whose data packages meet the Optimal Success Criteria. If none of the Concept Stage winners meet the Optimal Success Criteria, the reserved awards will be issued to the first three Concept Stage winners to meet the Essential Success Criteria during the submission window. Up to eight awards will be made after a merit-based review of all proposals.

Submissions will be reviewed as a batch after the solicitation period is closed. Applications will be accepted starting in early February 2026. Concept Stage award decisions are anticipated in Q3 2026.

The evaluation process and accompanying criteria are outlined below. Awards for Stage 1: Hit-to-Lead Up to six awards will be made in total. Up to two (2) of the six awards are reserved exclusively for Concept Stage winners that meet the Optimal or Essential Success Criteria within the specified submission window.

*All applicants must submit a Declaration of Intent and receive approval before their submissions can be reviewed. Rolling review “first-to-finish” Data packages may be submitted at any time during the submission window (anticipated to open in early 2027). Submissions will be reviewed in the order received, and awards will be made on a first-to-finish basis, subject to validation of the data.

“Reserved awards” for Concept Stage winners The two reserved awards are available only to eligible Concept Stage winners and may be earned at any time during the submission window. These reserved awards will be issued to the first two Concept Stage winners whose data packages meet the Optimal Success Criteria.

If none of the Concept Stage winners meet the Optimal Success Criteria, the reserved awards will be issued to the first two Concept Stage winners to meet the Essential Success Criteria during the submission window. Two success- criteria tracks Data packages may be submitted against one of two success criteria: Optimal Success Criteria or Essential Success Criteria, as defined in the Target Compound Profile.

Awards for Optimal submissions will be made on a rolling basis as soon as the data are reviewed and validated, until all available prizes for Stage 1 (that have not been reserved for Concept Stage winners) are awarded. Submissions that meet only the Essential Success Criteria will be held and considered at the end of the submission period. Essential awards will be made only if funding remains after all Optimal awards have been issued.

Rolling review “first-to-finish” Data packages may be submitted at any time during the submission window (anticipated to open in early 2027). Submissions will be reviewed in the order received, and awards will be made on a first-to-finish basis, subject to validation of the data.

Two success- criteria tracks Data packages may be submitted against one of two success criteria: Optimal Success Criteria or Essential Success Criteria, as defined in the Target Compound Profile. Awards for Optimal submissions will be made on a rolling basis as soon as the data are reviewed and validated, until all available prizes for Stage 1 (that have not been reserved for Concept Stage winners) are awarded.

Submissions that meet only the Essential Success Criteria will be held and considered at the end of the submission period. Essential awards will be made only if funding remains after all Optimal awards have been issued. “Reserved awards” for Concept Stage winners The two reserved awards are available only to eligible Concept Stage winners and may be earned at any time during the submission window.

These reserved awards will be issued to the first two Concept Stage winners whose data packages meet the Optimal Success Criteria. If none of the Concept Stage winners meet the Optimal Success Criteria, the reserved awards will be issued to the first two Concept Stage winners to meet the Essential Success Criteria during the submission window.

Concept Stage Evaluation Process & Criteria The SMART Antiviral Prize uses a two-stage review process: Written Submission Review Written Submission Review and Virtual Presentation (Pitch Call) Stage 1: Written Submission Review An expert judging panel will review, score, and rank all Concept Stage written submissions using the published evaluation criteria.

Scores and rankings will be based solely on the information provided in the written submission at the time of submission. Stage 2: Virtual Presentations (“Pitch Calls”) Based on rankings from Stage 1, the highest-scoring applicants will be invited to participate in a virtual presentation (“Pitch Call”) with the judging panel. The Administrator expects to invite fifteen (15) applicants.

To support a balanced portfolio, the Prize Administrator intends to invite at least two (2) applicants targeting each prioritized viral family ( Togaviridae and Flaviviridae ). Prize Award Recommendations Following Pitch Calls, judges will submit results—reflecting final scoring and prize recommendations—to Start2 for decision.

Consistent with the stated evaluation criteria and eligibility requirements, the final recommendations will support selection of eight (8) winners with at least one (1) winner from each prioritized viral family ( Togaviridae and Flaviviridae ). The submissions will be reviewed using the following evaluation criteria.

Scientific rationale and antiviral target strategy Judges will assess how clearly the submission explains its antiviral concept, including the proposed mechanism of action, relevance to broad-spectrum activity within one or more prioritized viral families, and strength of the supporting evidence (e.g., literature, public data, or preliminary in silico/experimental findings) that the target or pathway is essential, druggable, resistant to development of viral escape, and plausibly conserved across multiple viruses.

Development and regulatory strategy Judges will consider how well the submission lays out a realistic, coherent path from the current state of the program toward a Phase 1–ready small-molecule antiviral candidate, including key preclinical activities and milestones, anticipated regulatory needs, and a thoughtful approach to identifying and mitigating major technical, regulatory, and operational risks over the anticipated prize stages.

Capabilities, partnerships, and execution feasibility Judges will evaluate whether the entrant and any proposed partners have the expertise, resources, and collaborations needed to execute the plan, including relevant scientific and development capabilities, access to required infrastructure and IP/freedom to operate, and an overall program management approach that makes timely, high-quality delivery of the proposed work feasible.

In Stage 2 of the evaluation process, in addition to the written submission, judges will consider the following factors during the Pitch Call: Consistency with the written submission Clarity regarding key risks and proposed mitigation strategies Feasibility of near-term milestones Responsiveness to judges’ questions Target Compound Profile Measuring Success in Stage 1: Hit-to-Lead The SMART Antiviral Prize has outlined the set of target criteria for eligible entrants to reach by the end of Stage 1.

Applicants applying for Concept Stage funding should design a credible development plan with these milestones in mind to address early risks and reach the project goals within the data submission period. All information provided within is preliminary and subject to change. Specific criteria and requirements are currently being refined.

In the event of any inconsistency, the official SMART Antiviral Prize Terms & Conditions supersede this information. Desired Product Attributes for Small Molecule Broad-spectrum Antivirals This document outlines Desired Product Attributes that applicants may find useful when shaping antiviral concepts for submission to the SMART Antiviral Prize.

These attributes are provided as a draft and are subject to change as the prize design is further refined.

Treatment of acute, laboratory-confirmed infection caused by viruses within the Flaviviridae and/or Togaviridae family Treatment and prophylaxis Family wide label supported by bridging across a prespecified breadth panel Direct-acting antiviral (targets highly conserved viral factors) or indirect acting antiviral (targets host factors required for viral entry, replication, and/or persistence) Antiviral Activity (Breadth and EC50 ≤1 µM across all viruses in a predefined breadth panel Documented, acceptable level of resistance development with understanding of potential resistance across viral species EC50 ≤100 nM across all viruses in a predefined breadth panel; EC50 ≤1 µM across ALL pathogenic viruses within the family No evidence of emergence of resistance in clinical trials All populations, e.g., pediatrics (incl.

neonates), adults, older adults, pregnant/lactating, immunocompromised Contraindications, Use, Adverse Acceptable adverse event rate vs. benefit; manageable toxicity No black box warning or major precautions Some contraindications tolerated No severe interactions with routine drugs; monitor CYP pathway; may need dose adjustment with other medications Compatible with potential standard of care (SOC) options Well tolerated, mild or no side effects No significant contraindications or DDIs; compatible with most therapies Clinically meaningful improvement in time to symptom resolution for acute infections when compared to untreated patients Clinically meaningful reduction in symptom severity/progression to severe disease or hospitalization and strong prevention of progression or transmission, if applicable Prevention of chronic symptoms/post-viral sequelae Safety and tolerability profile supports evaluation for prophylactic indications Defined PK/PD; dosing maintains EC90 in target tissue(s) Antiviral activity (e.g., protein- adjusted 90% effective concentration pa-EC90)) supporting a PK/PD Index (PDI) ≥3 (e.g., predicted Ctrough/pa- EC90) Predictable and consistent PK/PD in all sub-populations; long half-life Dosing maintains 3x EC90 in target tissue(s) Antiviral activity supporting PDI≥10 where feasible Small molecule (at or below 900 daltons) Within 48 hours from symptom onset Maintains effectiveness when started 5 days from symptom onset; effective even with delayed diagnosis Suitable for treatment with extended protection providing sustained viral clearance for persistent infections 3 doses/day for up to 14 days, or as needed based on disease i Multiple routes, including oral and parenteral ≥ 2 years at 2-8˚C and/or RT, stable in field conditions ≥ 3 years at controlled RT, compatible with pandemic deployment Regulatory Path, Registration i Persistent infections caused by Chikungunya lead to prolonged viral presence (up to 28 days) and may need longer duration of treatment for sustained viral clearance.

Target Compound Profile Measuring Success in Stage 1: Hit-to-Lead The SMART Antiviral Prize has outlined the set of target criteria for eligible entrants to reach by the end of Stage 1. Applicants applying for Concept Stage funding should design a credible development plan with these milestones in mind to address early risks and reach the project goals within the data submission period.

All information provided within is preliminary and subject to change. Specific criteria and requirements are currently being refined. In the event of any inconsistency, the official SMART Antiviral Prize Terms & Conditions supersede this information.

Thank you for your interest in the SMART Antiviral Prize. Since the prize challenge is looking for innovators who can accelerate development of broad-spectrum, small molecule antiviral therapies, teaming collaborations between diverse sets of innovators are encouraged to achieve these goals. If you or your organization would like to explore collaborations with other potential applicants, please complete the form below.

After a short vetting process, you will be contacted by VITAL, and your information will be added to the publicly accessible list below.

Organization Type ▾ Academia Startup (Biotech, AI) Large Pharma/Biotech Nonprofit Service Provider (CRO, CDMO) Other Clear Virus Family of Interest ▾ Togaviridae Flaviviridae Other Clear Expertise ▾ Discovery & Design AI / ML Virology & Infection Models Development / ADME / Safety CMC / Formulation Manufacturing Clinical / Regulatory Clear Virology & Infection Models Synko Pharma Corp. seeks to develop broad spectrum antivirals based on their synthetic carbohydrate receptor (SCR) technology.

SCRs are small molecules with molecular weights below 900 that operate by inhibiting the role of envelope glycans in the viral lifecycle, and we have already demonstrated in vitro and in vivo broad spectrum antiviral activity, including against multiple flaviviridae.

Current Research Focus Areas Synko Pharma Corp. focuses on developing broad spectrum antivirals, and the current stage of development is TRL3/4 based on the medical countermeasures roadmap. This includes identifying and validating a novel target (viral envelope glycans), in vitro activity against live viruses, and assays to demonstrate that the origin of antiviral activity of our countermeasures is glycan binding.

What We’re Seeking in Teaming Partners Synko will be seeking partners for clinical formulations, non-GMP and GMP manufacturing, and running clinical trials. IIT Research Institute (IITRI) Service Provider (CRO, CDMO) Virology & Infection Models Development / ADME / Safety IITRI is a midsized nonprofit preclinical CRO with extensive experience and a long history of supporting antiviral development.

We are a fully accredited facility with ABSL-2 and ABSL-3 containment suites available for studies involving pathogenic agents and medical countermeasures, and inhalation exposure suites available for studies in small and large animals. Our GLP-compliant bioanalytical laboratory is onsite for efficient and transport-free coordination of study teams and samples.

Current Research Focus Areas IITRI specializes in infectious disease vaccine and therapeutic development, IND-enabling programs, and inhalation toxicology for biotech and government sponsors. We have experience working with members of the Togaviridae and Flaviviridae families, along with many other emerging and relevant pathogens.

Active research areas include aerosol transmissible pathogens, therapeutic response characterization, and evaluation of antiviral delivery platforms across our multidisciplinary scientific teams. What We’re Seeking in Teaming Partners IITRI is interested in collaborating with organizations developing innovative antiviral platforms or strategies that require infectious challenge models and comprehensive safety programs.

We can support exploratory, non GLP infectious disease evaluations in ABSL 2 and ABSL 3 environments, and fully GLP compliant toxicology and pharmacology studies. Our integrated scientific teams provide continuity across discovery, proof of concept, and data for IND submissions. We seek partners who value direct scientific engagement and a collaborative approach to advancing antiviral and biodefense technologies.

CMC / Formulation Manufacturing NanoViricides is developing antiviral drugs using a novel nanomedicines technology. For SMART Prize Project#1, we intend to design & develop novel pan-Flavivirus Entry-Inhibitors that would disturb virus surface. In Project#2, we plan to design & develop novel pan-RNA virus RDRP-suicide-inhibitors.

We have strong in-house capabilities for chemistry, synthesis, scale-up, cGMP manufacture, & clinical-scale product fill-and-finish. We depend upon collaborators for Non-clinical studies. Current Research Focus Areas Lead direct-acting, cell-mimetic, broad-spectrum antiviral, NV-387: Strong in animal models vs disparate viruses; Influenza, RSV, CoronaV, OrthopoxV, Measles.

Ph I successful. Ph II vs MPox scheduled, DRC. TRL4/5.

NV-HHV-1, HVEM-mimetic pan-herpesvirus drug. NV-HIV-1, pan-HIV CD4 & CCR5 sites presenting, presumably functional cure. TRL3/4.

Small molecules – Various broad-spectrum RDRP-inhibitory nucleotide analogs; NV-485, TRL3, successful animal models RSV, Measles; expect TogaV& FlaviV also. What We’re Seeking in Teaming Partners In vitro (including BSL3) and In vivo antiviral assays & models for efficacy and infected species safety tolerability studies. Viruses of interest: Flaviviridae, mainly DENV-1,2,3,4, ZikaV, YFV, WNV incl.

Clinical isolates, for Project#1 Entry Inhibitors. For Project#2 RDRP Inhibitors, Togaviridae: CHIKV, RossRV, BarmahFV, also BSL3 Enceppalitic viruses. DMPK studies including DDI, PPB, SMIL, Metabolic.

Non-GLP and GLP PK studies. IND-enabling Non-clinical Safety-Tox and other studies. Brown Lab: University of Florida Virology & Infection Models Development / ADME / Safety We help de-risk and accelerate antiviral development using advanced PK/PD-driven infection models and translational modeling.

Our team designs dosing and combination strategies that maximize efficacy, limit resistance, and minimize toxicity for medically important viruses, including flaviviruses and togaviruses, with full BSL-2/ABSL2 and BSL-3/ABSL3 select-agent capabilities.

Current Research Focus Areas We are able to use our PK/PD infection and mathematical models to design optimal dosing strategies for antiviral agents that will improve therapeutic outcomes in patients. We are able to de-risk development by identifying the optimal dose and dosing interval for agents as monotherapy or in combination that will maximize efficacy and prevent resistance emergence with minimal toxicity.

We use in vitro and small rodent in vivo models. Our labs are certified for BSL-2 up to select agent BSL-3 work What We’re Seeking in Teaming Partners We seek teaming partners with identified antiviral hit or lead compounds and complementary discovery or development expertise.

Our ideal collaborators contribute medicinal chemistry and clinical translation capabilities to support rapid PK/PD optimization and advancement toward first-in-human studies. GiwoTech is building an AI-driven platform that simulates protein dynamics and molecular interactions at atomic resolution to accelerate precision drug discovery and transform previously undruggable targets into viable therapeutics.

Current Research Focus Areas An AI-driven molecular simulations platform to create digital twins of biological systems, focusing on protein-protein interactions and viral mechanisms. Our physics-informed machine learning simulations decodes protein dynamics at atomic resolution to unlock previously undruggable targets for therapeutic discovery.

Currently NSF STTR Phase I-funded with BARDA support, advancing core simulation engine development to compress drug discovery timelines from years to months.

What We’re Seeking in Teaming Partners We seek collaborators with expertise in: (1) experimental viral characterization and BSL-3 assay development for validation of computational predictions; (2) pharmaceutical manufacturing and GMP-scale production of antiviral therapeutics; (3) clinical trial design and regulatory expertise for FDA pathway navigation.

Partners should bring existing pharma relationships, translational biology validation pipelines, o bridge computational predictions to clinical outcomes. Allegheny Biosciences, LLC Computational drug discovery services spanning scaffold-based generative AI, goal-directed molecular optimization, and ADMET prediction.

Multiple generative architectures and tools are available depending on project needs, with models fine-tuned for specific viral targets as required. The approach combines AI-driven exploration with medicinal chemistry knowledge to generate practical molecules against targets of interest. Current Research Focus Areas Antiviral target analysis and small molecule design for Flavivirus and Alphavirus families.

Broad domain expertise spanning clinical pharmacology, structural biology, toxicology, and drug metabolism informs the computational work. Current infrastructure supports de novo generation, hit expansion, multi-objective optimization, and ADMET property prediction. What We’re Seeking in Teaming Partners Collaborators with virology expertise and antiviral assay capabilities to validate computational predictions.

Ideal partners have experience testing compounds against Togaviridae or Flaviviridae targets. Synthetic chemistry access is helpful but can be addressed through CROs as needed. Computational hit generation, optimization, and property prediction offered in return.

Open to joining established teams or forming new collaborations. Atea is a clinical stage biopharmaceutical company working to address unmet medical needs with innovative oral antiviral therapies targeting viral RNA-dependent RNA polymerases.

With a platform of more than 2500 nucleoside and nucleotide prodrugs with extensive SAR, we can identify highly potent antivirals such as AT-2490 – a broad-spectrum polymerase inhibitor against both flaviviruses and togaviruses. Ongoing synthesis of new compounds through SAR may lead to new potential candidates.

Current Research Focus Areas Broad spectrum nucleotide with demonstrated nanomolar in vitro activity against Dengue, Zika, Yellow Fever, Japanese Encephalitis, West Nile, Powassan, and Chikungunya. A potential clinical candidate, AT-2490, has been identified to progress into IND enabling studies to include additional testing against Flavivirus and Togavirus genotypes/serotypes/strains.

Test in relevant animal efficacy models and other IND enabling activities including DMPK, nonclinical toxicology, and CMC development. What We’re Seeking in Teaming Partners In vitro (including BSL-3 labs) and in vivo testing (in relevant animal models, such as non-human primates for Chikungunya) against viruses to include Dengue, Zika, Yellow Fever, West Nile, Powassan, and Chikungunya.

DMPK studies including in vitro DDI, PPB, metabolic stability, and cross-species metabolic ID in hepatocytes. Non-clinical toxicology studies in 2 species, GLP safety pharmacology and toxicology.

Southern Research: A Non-profit Research Institute & Full-Service CRO Service Provider (CRO, CDMO) Virology & Infection Models Mission-driven nonprofit research institute: Southern Research is an 85-year-old nonprofit with ~200 employees translating scientific discovery into real-world impact through partnerships with government, industry, and academia.

Academic and clinical integration: Southern Research leverages direct access to UAB’s core laboratories, clinical trial networks, and clinician-scientist expertise - reducing development risk and accelerating translation from discovery into and through clinical trials. Current Research Focus Areas Full service nonclinical CRO with deep expertise and experience in alphaviruses and flaviviruses.

Federal select agent program; A/BSL-3 facilities and laboratories. AAALAC accredited with small and large animal capacity, including NHPs. End-to-end small molecule discovery from target identification to clinical lead.

Advanced and complex synthetic chemistry capabilities. High-throughput screening and automation/robotics infrastructure. Early and late-stage clinical trial sample testing (GCLP).

What We’re Seeking in Teaming Partners Novel, high-impact antiviral targets suitable for small-molecule discovery and optimization programs. Chemical assets or scaffolds with potential for maturation into differentiated clinical leads and backup candidates. Phenotypic discovery opportunities enabling development of novel antiviral or host-directed therapeutic programs.

Antiviral or host-directed programs requiring integrated nonclinical support, including non-GLP and GLP studies. A/BSL-4 capabilities to complement our high-containment virology and translational research capabilities.

Service Provider (CRO, CDMO) Virology & Infection Models Development / ADME / Safety Artemis Bioservices is a GLP‑certified CRO supporting BARDA‑aligned development of direct‑acting antivirals with deep expertise in Flaviviridae and Togaviridae.

Artemis provides in‑vitro antiviral efficacy testing, viral load reduction, and live and pseudotyped virus neutralization assays to assess family‑wide breadth, mechanism‑of‑action and resistance risk. Artemis has supported and executed multiple IND‑ready antiviral programs from discovery through clinical stages.

Current Research Focus Areas Our primary focus is providing GLP‑certified virology and immunology services as a subcontracting CRO supporting BARDA‑aligned antiviral programs. Artemis Bioservices specializes in translational in‑vitro and ex‑vivo antiviral efficacy testing, with deep expertise in Flaviviridae and Togaviridae.

We support partners from early discovery through IND‑ready stages by delivering robust data on antiviral activity, mechanism‑of‑action, resistance risk and correlates of protection. What We’re Seeking in Teaming Partners We seek teaming partners developing direct‑acting antivirals who require robust, BARDA‑aligned preclinical datasets.

Ideal partners bring antiviral assets, chemistry, PK/PD, or clinical development expertise, while Artemis provides GLP virology and immunology services covering efficacy, breadth, and resistance risk. We have supported multiple startup companies in building high‑quality datasets that enabled successful investor engagement and competitive funding and partnering outcomes.

Service Provider (CRO, CDMO) Virology & Infection Models Battelle provides capabilities to support antiviral development against viruses from the Flaviviridae and Togaviridae families, including existing in vitro and in vivo models for efficacy assessments and expertise in the development of such models to assess novel technologies.

Our BSL-3+ containment facility is the largest privately maintained in the US and is operated under a well-established quality management system, and we provide a team of experts to support rapid evaluation of MCMs. Current Research Focus Areas Battelle has capabilities to support throughout product development using an established roadmap demonstrated by successful support of multiple product licensures via FDA Animal Rule.

Our specialized capabilities being preclinical development supporting in vitro and in vivo efficacy assessments.

What We’re Seeking in Teaming Partners Battelle seeks potential teaming partners in need of virology expertise and laboratory infrastructure (up to enhanced BSL-3) to support small molecule development and evaluation by being a partner with high quality, proven track record supporting therapeutic development against emerging infectious diseases spanning TRL-1 to TRL-7/8.

MRC University of Glasgow Centre for Virus Research Virology & Infection Models The MRC Centre for Virus Research is a leading UK institute studying human and animal viruses. Its research spans virus biology and evolution, sequencing, bioinformatics, and viral genomics.

It is a standing national capability for virus discovery, preparedness and response, enabling rapid progression from early detection to actionable innovations to tackle viral threats in the UK and worldwide. Current Research Focus Areas Within the MRC Centre for Virus Research Translational Hub,